Mark Small

3.2k total citations
126 papers, 2.2k citations indexed

About

Mark Small is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Sociology and Political Science. According to data from OpenAlex, Mark Small has authored 126 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Pulmonary and Respiratory Medicine, 34 papers in Physiology and 24 papers in Sociology and Political Science. Recurrent topics in Mark Small's work include Chronic Obstructive Pulmonary Disease (COPD) Research (34 papers), Asthma and respiratory diseases (31 papers) and Respiratory and Cough-Related Research (16 papers). Mark Small is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (34 papers), Asthma and respiratory diseases (31 papers) and Respiratory and Cough-Related Research (16 papers). Mark Small collaborates with scholars based in United States, United Kingdom and Germany. Mark Small's co-authors include Bo Ding, Solomon M. Fulero, C. A. Elizabeth Brimacombe, Gary L. Wells, Steven Penrod, Roy S. Malpass, Victoria Higgins, Susan P. Limber, Ulf Holmgren and James Siddall and has published in prestigious journals such as SHILAP Revista de lepidopterología, Environmental Science & Technology and American Psychologist.

In The Last Decade

Mark Small

112 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Small United States 24 859 724 490 401 244 126 2.2k
Martin Anderson Sweden 21 544 0.6× 237 0.3× 144 0.3× 40 0.1× 261 1.1× 76 1.4k
Angelo Barbato Italy 31 1.4k 1.6× 810 1.1× 477 1.0× 21 0.1× 757 3.1× 143 3.4k
Lung-Chang Chien United States 25 259 0.3× 126 0.2× 86 0.2× 115 0.3× 106 0.4× 99 2.2k
So Lun Lee Hong Kong 24 545 0.6× 435 0.6× 48 0.1× 135 0.3× 365 1.5× 75 2.5k
Maria Antonietta Stazi Italy 27 121 0.1× 329 0.5× 209 0.4× 157 0.4× 409 1.7× 91 2.7k
Martin Kharrazi United States 35 695 0.8× 220 0.3× 92 0.2× 635 1.6× 169 0.7× 80 3.6k
Geir Jacobsen Norway 34 329 0.4× 292 0.4× 86 0.2× 194 0.5× 271 1.1× 139 4.4k
Gregory S. Andérson Canada 31 170 0.2× 294 0.4× 274 0.6× 47 0.1× 735 3.0× 105 2.9k
Charles Kamen United States 37 639 0.7× 282 0.4× 1.0k 2.1× 118 0.3× 507 2.1× 159 3.6k
Kaja Z. LeWinn United States 30 78 0.1× 194 0.3× 123 0.3× 576 1.4× 470 1.9× 119 2.9k

Countries citing papers authored by Mark Small

Since Specialization
Citations

This map shows the geographic impact of Mark Small's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Small with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Small more than expected).

Fields of papers citing papers by Mark Small

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Small. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Small. The network helps show where Mark Small may publish in the future.

Co-authorship network of co-authors of Mark Small

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Small. A scholar is included among the top collaborators of Mark Small based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Small. Mark Small is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Small, Mark, et al.. (2024). The diagnostic journey of pulmonary arterial hypertension patients: results from a multinational real-world survey. Therapeutic Advances in Respiratory Disease. 18. 2683798214–2683798214. 6 indexed citations
2.
Benson, Victoria S., James Siddall, Mark Small, et al.. (2024). Sub-Optimal Disease Control and Low Blood Eosinophil Testing Frequency in Chinese Adult Patients with Asthma Receiving GINA Step 4/5 Treatment: A Real-World Study. Journal of Asthma and Allergy. Volume 17. 1041–1054.
3.
Orozco‐Levi, Mauricio, Rogério Souza, G. Meyer, et al.. (2024). Pathway to care, treatment and disease burden of pulmonary arterial hypertension: a real-world survey of physicians and patients in Latin America. BMJ Open. 14(12). e087263–e087263. 2 indexed citations
4.
Vizza, Carmine Dario, Rogier Klok, Mark Small, et al.. (2024). Clinical Characteristics and Treatment of Patients Diagnosed with Pulmonary Arterial Hypertension: A Real-World Study in the USA, Europe and Japan. Advances in Therapy. 42(1). 193–215. 1 indexed citations
5.
6.
Small, Mark, et al.. (2024). Social-Relational Contexts of Child Participation: Profiles of Children’s Views in 18 Countries. Child Indicators Research. 17(4). 1495–1521. 2 indexed citations
7.
Lancaster, Lisa, Francesco Bonella, Yoshikazu Inoue, et al.. (2021). Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden. Respirology. 27(1). 66–75. 23 indexed citations
8.
Rosopa, Patrick J., et al.. (2021). Faculty Perception of the Contribution of Start-up Packages to Professional Development. Innovative Higher Education. 46(4). 481–497.
9.
Silver, Jared, Michael Bogart, Néstor A. Molfino, et al.. (2021). Factors leading to discontinuation of biologic therapy in patients with severe asthma. Journal of Asthma. 59(9). 1839–1849. 14 indexed citations
10.
Coteur, G., Yoshikazu Inoue, Vincent Cottin, et al.. (2020). PRS78 Burden of Idiopathic Pulmonary Fibrosis (IPF) on Quality of Life (QOL), Work Productivity and Healthcare Use. Value in Health. 23. S732–S732.
11.
Scott, Megan, et al.. (2020). PDB98 THE IMPACT OF SEVERE VASOMOTOR SYMPTOMS ON WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT: FINDINGS FROM A US REAL WORLD SURVEY. Value in Health. 23. S126–S126. 1 indexed citations
12.
Small, Mark, et al.. (2018). The impacts of morning, daytime, and nighttime symptoms on disease burden in real-world patients with COPD. International Journal of COPD. Volume 13. 1557–1568. 8 indexed citations
13.
14.
Small, Mark, James Piercy, James Pike, & Annamaria Cerulli. (2014). Incremental Burden of Disease in Patients Diagnosed with Pulmonary Arterial Hypertension Receiving Monotherapy and Combination Vasodilator Therapy. Advances in Therapy. 31(2). 168–179. 10 indexed citations
15.
Chrystyn, Henry, et al.. (2013). Impact of patients' satisfaction with their inhalers on treatment compliance and health status in COPD. Respiratory Medicine. 108(2). 358–365. 114 indexed citations
16.
Jones, Paul, Gilbert Nadeau, Mark Small, & L. Adamek. (2013). Characteristics of a COPD population categorised using the GOLD framework by health status and exacerbations. Respiratory Medicine. 108(1). 129–135. 49 indexed citations
17.
Melton, Gary B., Ross A. Thompson, & Mark Small. (2002). Toward a child-centered, neighborhood-based child protection system : a report of the consortium on children, families, and the law. Praeger eBooks. 17 indexed citations
18.
Small, Mark. (2001). Public Service and Outreach to Faith-Based Organizations. Journal of higher education outreach & engagement. 6(2). 57–65. 2 indexed citations
19.
Small, Mark, et al.. (1988). Privacy Regulation of Computer-Assisted Testing and Instruction. Washington law review. 63(4). 841.
20.
Small, Mark. (1988). Performing "Competency to Be Executed" Evaluations: A Psycholegal Analysis for Preventing the Execution of the Insane. Nebraska law review. 67(3). 8. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martin Anderson Breakdown of academic impact, for papers by Angelo Barbato Breakdown of academic impact, for papers by Lung-Chang Chien Breakdown of academic impact, for papers by So Lun Lee Breakdown of academic impact, for papers by Maria Antonietta Stazi Breakdown of academic impact, for papers by Martin Kharrazi Breakdown of academic impact, for papers by Geir Jacobsen Breakdown of academic impact, for papers by Gregory S. Andérson Breakdown of academic impact, for papers by Charles Kamen Breakdown of academic impact, for papers by Kaja Z. LeWinn
Rankless by CCL
2026